title: Changes in cognitive functioning following treatment of late-life depression.
abstract: OBJECTIVE
  Knowledge of the relationship between various clinical characteristics and cognitive functioning is advancing, but little is known about the cognitive response to treatment for geriatric depression. The purpose of this study was to examine the cognitive response to treatment for patients with late-life depression.
  
  
  METHODS
  Subjects included 45 nondemented, elderly depressed patients who achieved remission after 12 weeks of antidepressant treatment and 20 elderly comparison subjects. All subjects were administered a battery of clinical measures, including cognitive screening instruments, before and after treatment.
  
  
  RESULTS
  As a group, the elderly depressed patients showed a small improvement in overall cognitive functioning after treatment. Among depressed patients with concomitant cognitive impairment at baseline, performance on the Mattis Dementia Rating Scale domains of conceptualization and initiation/perseveration improved significantly relative to those of depressed patients with normal cognition. Despite the improvement following treatment, the overall level of cognitive functioning in the elderly depressed patients with cognitive impairment at baseline remained mildly impaired, especially in the memory and initiation/perseveration domains.
  
  
  CONCLUSIONS
  Elderly depressed patients with cognitive impairment may experience improvement in specific domains following antidepressant treatment but may not necessarily reach normal levels of performance, particularly in memory and executive functions. This subgroup of late-life depression patients is likely at high risk of developing progressive dementia.
authors.affiliation: Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Butters
authors.forename: J T
authors.initials: JT
authors.lastname: Becker
authors.forename: R D
authors.initials: RD
authors.lastname: Nebes
authors.forename: M D
authors.initials: MD
authors.lastname: Zmuda
authors.forename: B H
authors.initials: BH
authors.lastname: Mulsant
authors.forename: B G
authors.initials: BG
authors.lastname: Pollock
authors.forename: C F
authors.initials: CF
authors.lastname: Reynolds
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology; D015897:Comorbidity; D003704:Dementia / Q000175:diagnosis / Q000453:epidemiology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009661:Nortriptyline / Q000627:therapeutic use; D017374:Paroxetine / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017374:Paroxetine; D009661:Nortriptyline